Cascade Nanoreactor Based on Mo 2 C MXene for NIR-II-Activated Multimodal Therapy of Cancer

View at publisher
Authors: Lu Zhao, Jianfeng Li, Xuehui Zhang, Yunfeng Bai, Feng Feng
Cited by: 1
References: 46

Abstract

The complexity and dynamic nature of the tumor microenvironment (TME) pose significant challenges to effective cancer therapy. Therefore, the development of nanocomposites capable of fully exploiting TME characteristics is crucial for achieving precise and efficient tumor treatment. Herein, the cascade nanoreactor PDA@Mo 2 C-MnO 2 -Au/Apt-M (PMMAA) was successfully constructed based on Mo 2 C MXene and nanozymes. This nanoreactor leveraged the TME to achieve NIR-II-triggered combined photothermal therapy and chemodynamic therapy (PTT/CDT) with active targeting capability. PMMAA exhibited a photothermal conversion efficiency of 41.89% under NIR-II laser irradiation, enabling efficient thermal ablation of tumor tissues. In the acidic TME, the loaded MnO 2 NPs mediated Fenton-like reactions that selectively converted endogenous H 2 O 2 into highly cytotoxic • OH, realizing intelligent TME-responsive CDT. Notably, the embedded Au NPs in the nanoreactor exhibited glucose oxidase-like activity, catalyzing the conversion of glucose into H 2 O 2 and gluconic acid, thereby simultaneously elevating both H 2 O 2 levels and local acidity to establish a self-amplifying catalytic cascade. This nanozymes-based cascade amplification effect significantly enhanced CDT efficacy by promoting • OH generation. Systematic evaluations demonstrated that the nanoreactor possessed dual enzyme-mimicking activities (POD-like and GOx-like), excellent biosafety, and remarkable tumor suppression effects. This study established a new paradigm for precision cancer therapy through the rational design of multifunctional nanozymes-enhanced CDT capable of dynamically modulating the TME.

Fields of Study & Subjects

Nanoplatforms for cancer theranostics Advanced Nanomaterials in Catalysis MXene and MAX Phase Materials

Publication details

Journal / source
Molecular Pharmaceutics
Publisher
American Chemical Society (ACS)
Volume
23
Issue
3
Pages
1955–1968
Publication date
2 February 2026
Language
EN